NeuroDerm Ltd. (NDRM) Sees Unusually-High Trading Volume
Shares of NeuroDerm Ltd. (NASDAQ:NDRM) saw strong trading volume on Monday . 69,348 shares changed hands during mid-day trading, a decline of 6% from the previous session’s volume of 73,963 shares.The stock last traded at $17.16 and had previously closed at $17.04.
A number of equities analysts have recently weighed in on the company. Roth Capital reaffirmed a “buy” rating on shares of NeuroDerm in a research note on Sunday, May 29th. Oppenheimer Holdings Inc. assumed coverage on NeuroDerm in a research note on Saturday, April 2nd. They issued a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. NeuroDerm has an average rating of “Buy” and an average target price of $24.70.
The stock’s market capitalization is $377.29 million. The company’s 50-day moving average price is $17.02 and its 200 day moving average price is $15.34.
NeuroDerm (NASDAQ:NDRM) last issued its quarterly earnings results on Thursday, May 26th. The company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.10. On average, equities research analysts anticipate that NeuroDerm Ltd. will post ($1.52) EPS for the current year.
NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company is developing ND0612H for the treatment of patients suffering from severe Parkinson’s disease; ND0612L for the treatment of patients at the moderate stage of Parkinson’s disease that can no longer control motor complications with oral levodopa, and ND0680 for the treatment of a small subset of severe Parkinson’s disease patients, whose symptoms have advanced to a severe stage, requiring even higher doses of LD/CD than ND0612H is designed to provide.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.